Ianalumab
Ianalumab is a human monoclonal antibody designed for the treatment of diseases that are mediated by the B cell activating factor (BAFF), such as systemic lupus erythematosus and Sjögren's syndrome. It was developed by Novartis.
Mechanism of action[edit | edit source]
Ianalumab works by binding to the B cell activating factor (BAFF), a protein that plays a key role in the survival and proliferation of B cells. By blocking BAFF, ianalumab reduces the number of B cells, which are thought to contribute to the development of autoimmune diseases.
Clinical trials[edit | edit source]
Ianalumab has been tested in several clinical trials. In a phase II trial for systemic lupus erythematosus, ianalumab showed a significant reduction in disease activity compared to placebo. A phase III trial is currently underway.
Side effects[edit | edit source]
The most common side effects of ianalumab include infections, headache, and nausea. Serious side effects can include severe infections and allergic reactions.
See also[edit | edit source]
- Monoclonal antibodies
- Systemic lupus erythematosus
- Sjögren's syndrome
- B cell activating factor
- Novartis
References[edit | edit source]
| Ianalumab Resources | ||
|---|---|---|
|
| |
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
